NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Looking ahead, Google’s new CFO Ruth Porat forecast capital expenditures (CAPEX) for fiscal year 2025, which is expected to ...

and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Wall Street trading got off to a mixed start early on Wednesday as share price losses at tech giants Alphabet and AMD put ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

2-Year U.S. Treasury Note Continuous Contract $102.879 0.031 0.03% 5-Year U.S. Treasury Note Continuous Contract $106.734 0.164 0.15% 10-Year U.S. Treasury Note Continuous Contract $109.531 0.328 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Insider activity is seldom enough to move a market independently but can signal how a company’s management thinks. Exclusive content, detailed data sets, and best-in-class trade insights to ...